variants may affect the activity of the DNA regulatory elements (DREs) and, under specific circumstances, lead to dysregulation of gene expression. This is mediated by long-range 3-dimensional (3D) chromatin-chromatin interactions where the regulated candidate genes can be located up to ≈1 MB away [10] [11] [12] -a distance much larger than is normally used to annotate candidate genes in GWAS. These candidate genes can be identified by capturing the physical chromatin-chromatin interaction between a known disease susceptibility locus and the promoter of the gene(s) it presumably regulates. 13 Here we systematically apply this principle (study design is summarized in Figure) to variants identified by large meta-analyses of GWAS for CAD and LAS, altogether assaying 47 previously identified susceptibility loci. 2, 3 Atherosclerotic disease starts in the endothelial lining of the affected arteries and involves attraction and proliferation of monocytes.
14 Therefore, we studied 37 loci that colocalize with active DRE in human monocytes or in cardiac endothelial cells. We used circular chromosome conformation capture sequencing (4C-seq) to identify candidate genes based on their physical interaction with one of the active DRE.
See Clinical Perspective

Methods
Cell Culture
Primary commercially available human cardiac endothelial cells that were isolated by enzymatic detachment (Lonza Clonetics) were cultured in Roswell Park Memorial Institute-1640 with 10% FCS and standard supplements. Cells were harvested for 4C template preparation by trypsinization at 60% to 80% confluence.
Monocyte Isolation
Human peripheral blood was collected from a healthy donor in sodium-heparin tubes. Peripheral blood mononuclear cells were isolated by Ficoll-Paque gradient centrifugation. PMBCs were incubated with magnetic CD14 + microbeads (Milteny, order nr. 130-050-201) according to manufacturer's manual. Thereafter, cells were magnetically separated by the AutoMACS Separator; the positive fraction (monocytes) was used for 4C template preparation.
4C Template Preparation
The 4C template was prepared as previously described. 13 Summarized, 10×10 6 cells were used per cell type (monocytes and cardiac endothelial cells). Cells were crosslinked in 2% formaldehyde. After chromatin isolation, the chromatin was digested with DpnII (NEB, No R0543L). Digestion was stopped through heat inactivation of the restriction enzyme. Samples were diluted and ligated by T4 DNA ligase. The second digestion was performed with CviQI (NEB, No R069S) and inactivated by phenol:chloroform extraction. The chromatin was diluted for the final T4 ligation, and the chromatin was purified. The quality of digestion and ligation was assessed on agarose gels.
Viewpoint Selection and Primer Design
All single-nucleotide polymorphisms (SNPs) from Table 2 and the young-CAD SNP (rs16986953) from the CARDIoGRAMplusC4D paper 2 (n=47) and the 2 replicated SNPs (rs2383207 and rs2107595) from METASTROKE 3 were considered for viewpoint design (Table VIII in the Data Supplement). When the SNPs within the susceptibility locus were <15 000 bp apart (eg, rs12740374, rs602633, and rs599839 in the SORT1 region), only 1 SNP was selected as a viewpoint. Susceptibility loci that overlapped with active DRE were identified through formaldehyde-assisted isolation of regulatory elements, the presence of H3K4Me1, H3K4Me3, H3K27Ac, H3K4Me2 or H3K9Ac, EP300, or transcriptional repressor CTCF binding sites or DNase hypersensitivity sites (Table IX in the Data Supplement) . DRE falling within the susceptibility locus coordinates were considered overlapping with the susceptibility locus. The primers were designed as described previously. 13 Primer sequences are listed in Table  VIII in the Data Supplement. In summary, the primers were designed in a window of 5 kb up-and downstream from the associated SNP. Forward and reverse primers were designed at least 300 bp apart. Forward (reading) primers were designed on top of the first restriction enzyme site. The reverse (nonreading) primer was designed close to (maximum 100 bp away from) the second restriction enzyme site. In case no primer pair could be designed within the initial window, the window was extended 5 kb up-and downstream (n=8). In the case of rs1561198, this did not result in a suitable primer, so a primer pair that was 299 bp apart was selected for this viewpoint.
4C-Seq Library Preparation
4C-sequencing library preparation was performed as described previously, 13 with minor adaptations to make the protocol compatible with the large number of viewpoints: the polymerase chain reaction (PCR) of 4C template was performed with 600 ng (monocytes) or 1.6 μg (coronary 
endothelial cells) of 4C template per reaction. Eight to 10 primer pairs were multiplexed in the initial PCR reaction (primer sequences are listed in Table VIII in the Data Supplement). Primers pairs were pooled according to primer efficiency (based on intensity on gel electrophoresis signal after PCR on test template). PCR products were purified after an initial PCR reaction of 6 cycles (reaction volume=200 μL) and divided among 8 to 10 PCR reactions containing single primer pairs for another 26 cycles (reaction volume=25 μL). Thereafter, PCR products derived from the same cells were pooled in equimolar amounts, and a final 6 cycle PCR reaction containing 20 ng of pooled PCR product (reaction volume=100 μL) was performed with primers that contained sequencing adaptor sequences. All fragments >700 bp were removed using size selection on a 1% agarose gel followed by gel extraction of the selected products (Qiagen, No 28704). Quality measures for the 4C library preparation and sequencing can be found in Figure I in the Data Supplement.
Sequencing
Libraries were sequenced using the HiSeq2500 platform (Illumina) according to the manufacturer's protocol, producing 50 bp single-end reads.
Data Analysis
The raw sequencing reads were demultiplexed based on viewpoint-specific primer sequences. Reads were then trimmed to 16 bases and mapped to an in silico generated library of fragends (fragment ends) neighboring all DpnII sites in human genome (NCBI37/hg19), using the custom Perl scripts. No mismatches were allowed during the mapping, and the reads mapping to only 1 possible fragend was used for further analysis.
Identification of the Interacting Genes
First, we calculated the number of covered fragends within a running window of k fragends throughout the whole chromosome where the viewpoint is located. The k was set separately for every viewpoint so it contains on average 20 covered fragends in the area around the viewpoint (±100 kb). Next, we compared the number of covered fragends in each running window to the random distribution. The windows with significantly higher number of covered fragends compared with random distribution (P<10 -8 based on binominal cumulative distribution function; R pbinom) were considered as significant 4C-seq signal. The following criteria were defined for the identification of the candidate genes; (1) the transcriptional start site colocalizes with 9 CDKN2BAS rs1333049, rs3217992, rs2383207
*Only genes that have their interacting viewpoint as eQTL or genes with a significant gene-based P value (P<6.97×10 −6 by gene-based test using VEGAS (corrected for multiple-testing 0.05/22 phenotypes×326 available genes) are depicted. The full list of genes identified by 4C-seq can be found in Table I in the Data Supplement. Susceptibility locus, name of the locus as given by CARDIoGRAMplusC4D or METASTROKE; viewpoint, SNP used as the focus point for the primer design of the 4C experiment; gene, gene physically interacting with viewpoint, determined by 4C-seq; bolded genes, genes that have previously been reported by CARDIoGRAMplusC4D or METASTROKE. BMI indicates body mass index; CAD, coronary artery disease; Chr indicates chromosome; eQTL, expression quantitative trait locus; GWAS, genome-wide association study; HDL, high-density lipoprotein; LDL, lowdensity lipoprotein; SNP, single-nucleotide polymorphisms; TC, total cholesterol; and TG, triglycerides. (Table IX in the Data Supplement) in the cell type from which the 4C-seq signal originated; and (3) the gene is expressed (reads per kilobase of transcript per million reads sequenced >0.5) in the assayed cell type.
Identification of Gene Expression
For monocyte expression, data from the Encyclopedia of DNA Elements (ENCODE) database were used (Table X in the Data Supplement). 15 For coronary endothelial cell expression, human microvascular endothelial cells (Lonza) were cultured on gelatin-coated plates in EGM2-MV (Lonza) supplemented with penicillin and streptomycin. Subsequently, Human microvascular endothelial cells were cultured for 20 hours in low serum medium (endothelial basal medium+0.5% FCS), followed by cell lysis and RNA isolation using the RNeasy isolation kit (Qiagen). Polyadenylated mRNA was isolated using Poly(A) Beads (NEXTflex). Sequencing libraries were made using the Rapid Directional RNA-Seq Kit (NEXTflex) and sequenced on Illumina NextSeq500 to produce single-end 75 base long reads (Utrecht Sequencing Facility). Reads were aligned to the human reference genome GRCh37 using STAR version2.4.2a. 16 Read groups were added to the BAM files with Picard's AddOrReplaceReadGroups (v1.98). The BAM files are sorted with Sambamba v0.4.5, and transcript abundances are quantified with HTSeq-count version 0.6.1p1 17 using the union mode. Subsequently, reads per kilobase of transcript per million reads sequenced are calculated with edgeR's rpkm() function.
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Pathway Analysis
The interacting genes (with and without expressed CARDIoGRAMplusC4D/METASTROKE genes) were analyzed using QIAGEN's Ingenuity Pathway Analysis (IPA, 2015 winter version, QIAGEN Redwood City, www.qiagen.com/ingenuity). We used IPA to identify canonical biological pathways within the Ingenuity Knowledge Base to which the interacting genes were mapped. Limits were set to only direct relationships that were experimentally observed in humans. We performed 6 rounds of pathway analysis, 3 in each of the cell types: 1 with only CARDIoGRAMplusC4D/ METASTROKE genes that were expressed in the cell type, 1 with the CARDIoGRAMplusC4D/METASTROKE genes supplemented by the newly identified genes, and 1 with the novel genes only.
Tracks and Plots
All tracks were accessed from the UCSC browser (hg19) (http://genome.ucsc.edu/). Regional plots were generated using LocusZoom version 1.3. 
Gene-Based Tests
Data for CAD were downloaded from the CARDIoGRAMplusC4D website (http://www.cardiogramplusc4d.org). We obtained summary statistics from GWAS on body mass index, blood lipids, including low-density lipoprotein, high-density lipoprotein, total cholesterol, and triglycerides, systolic and diastolic blood pressure, coronary calcification, fasting glucose, smoking behavior, and type 2 diabetes mellitus from public online resources, and data on intima-media thickness and plaque-presence via data request (Table XI in the Data Supplement). We used a VEGAS (Versatile Gene-Based Association Study) to calculate gene-based association statistics from the summary statistics of each interacting gene for each trait. The details of the methods applied by VEGAS have been described elsewhere. 20 In short, SNPs are mapped to the gene (in and around ±50 kb from 5′ and 3′ gene borders), and using the GWAS P value, a gene-based test statistic is calculated corrected for the underlying population LD structure. Finally, using simulations, an empirical gene-based P value of association with the phenotype is calculated per gene. VEGAS results were considered multiple testing significant if they were P<6.97×10 −6 (0.05/22 phenotypes×326 available genes in VEGAS).
Expression Quantitative Trait Locus Analysis in Stockholm Atherosclerosis Gene Expression
Within the STAGE (Stockholm Atherosclerosis Gene Expression) study, patients undergoing coronary artery bypass grafting surgery were sampled for 7 different tissues, namely atherosclerotic arterial wall, internal mammary artery, liver, skeletal muscle, subcutaneous fat, visceral fat, and fasting whole blood for RNA and DNA isolation. 21 Patients who were eligible for coronary artery bypass grafting and had no other severe systemic diseases (eg, widespread cancer or active systemic inflammatory disease) were included. For quality control in genotyping, SNPs filtered for minor allele frequency <5%, Hardy-Weinberg equilibrium P value <1×10 −6 , and call rate of 100%. Imputation was performed using IMPUTE2 with 1000 Genomes EUR as the reference. 22 Quality control for imputed genotypes used additionally an IMPUTE2 INFO score filter <0.3. After quality control a total of 5 473 585 SNPs remained. The Ethical committee of the Karolinska Hospital approved the study, and all patients gave written informed consent after the nature and possible consequences of the study were explained. An expression trait was tested for association with each genotyped and imputed SNP using Kruskal-Wallis test and false discovery rate to correct for multiple testing as described before. First, all cis-pairs of SNPs within 50 kb of the transcription start or end site for each gene were identified. Next, cis SNP-gene pairs were tested for association in all 7 STAGE tissues using kruX. 23 The P value for expression quantitative trait locus (eQTL) inclusion in kruX was set at 0.05. Finally, an empirical false discovery rate (FDR) estimate for each eQTL-gene pair was calculated using 10 permutations by shuffling patient IDs on genotype data. As a result, the most significant eQTL-gene association in each tissue was reported.
eQTL Analysis in Haploreg
Data on eQTL in healthy individuals were extracted from Haploreg version 4.1 (http://www.broadinstitute.org/mammals/haploreg/haploreg.php). The viewpoint SNPs and all SNPs in LD (r 2 >0.8) were used as input. From the output, for each interacting gene, the most significant eQTL within each tissue was extracted.
eQTL Analysis in Center for Translational Molecular Medicine Circulating Cells (CTMM)
CTMM Circulating Cells is a Dutch cohort from 4 different hospitals comprising 714 patients undergoing coronary angiography of whom blood was stored. Monocytes were isolated by density centrifugation followed by positive magnetic bead isolation (CD14), and expression was measured using the Illumina human HT-12 v3 Gene Expression BeadChip Array. After removal of samples with a median intensity of <50, 370 patients were included in the analysis. The data were quantile normalized and log2 transformed using the lumi R package. 24 Genotyping was performed using a customized Affymetrix Axiom Tx array containing 767 203 genetic markers. Community standard quality control was performed, filtering out samples with missingness >5%, outlying heterozygosity (±4 SD from the cohort mean), or inconsistent sex. Samples of non-European descent or those who were out of Hardy-Weinberg equilibrium (P<5×10 −5 ) were removed. In total, 622 samples were used in the current analysis. Untyped variants were imputed using a combined reference panel of the 1000 Genomes Project 25 and Genome of the Netherlands, 26 totaling >90 million genetic variants across the genome. We used the software packages SHAPEIT 27 for phasing and IMPUTE2 22 for imputation. Prior to cis-eQTL analysis, we filtered the imputed genotype data from Center for Translational Molecular Medicine based on minor allele frequency >0.5%, Hardy-Weinberg equilibrium P>1×10 −6 , Info-metric >0.9, and only focused on those variants in LD (r 2 ≥0.8) with the CAD-associated variants. We then used fastQTL (v2.184) 28 Atherosclerosis Genes and Chromatin Organization to perform I-eQTL analyses using a fixed range (based on the 4C interactions) around each probeID available on the expression array.
Mouse Knockout Models
Murine gene names were mapped to the genes as follows. First, a custom data file was downloaded from the HUGO Gene Nomenclature Committee (http://www.genenames.org/cgi-bin/download), including the approved gene name and the Mouse Genome Database ID from the Mouse Genome Informatics database, and a file containing all available phenotypic information for all knockout mice was downloaded from Mouse Genome Informatics (ftp://ftp.informatics. jax.org/pub/reports/index.html#pheno). Next, for all approved gene names of genes identified through 4C-seq, the mouse phenotypes were looked up by linking the Mouse Genome Informatics IDs. If no linkage could be made for the Mouse Genome Informatics ID, this was coded as no available mouse model. If a mouse model was available, but no phenotype was found, this was coded as no available phenotype. If a mouse model was specifically coded as not showing any phenotype on knockout, this was coded as a gene not resulting in any phenotype. Murine cardiovascular phenotypes were defined as a phenotype resulting in any of the following: impaired blood coagulation or abnormal platelets, abnormal glucose levels or homeostasis, abnormal vascular morphology, vascular remodeling or arterial differentiation, abnormal blood pressure, abnormal vasoconstriction, vasodilatation or vascular permeability, abnormal stress response of the heart, myocardial infarction, abnormal (circulating) lipid levels, abnormal fat morphology or amount, abnormal body weight, abnormal lipid droplet or fat cell size, abnormal macrophage response or inflammation, abnormal wound healing, arteritis, vasculitis, vascular occlusion, or atherosclerosis.
Human Knockout Models
The interacting genes were extracted from the supplementary tables of the studies of Sulem et al 29 and MacArthur et al. 30 For each of the interacting genes, all SNPs and indels resulting in human functional knockouts were reported.
Drug Targets
For the lookup of existing drugs that target any of the candidate genes, we used a custom-built drug pipeline that searches for druggene interactions using the Drug Gene Interaction Database, 31 which merged the most known drug-gene interaction databases, such as DrugBank 32 and PharmGKB. 33 We removed redundant results using the search tool for interactions of chemicals 34 and the World Health Organization's International Nonproprietary Names. 35 We tested overrepresentation of drug groups according to ATC codes 36 using Fisher exact tests.
Results
4C-Seq Identifies Additional Candidate Genes
We identified 37 active DREs that colocalize with susceptibility loci for CAD or LAS. Twenty-six DREs were active in both monocytes and coronary endothelial cells, 5 were only active in monocytes, and 6 were only active in coronary endothelial cells (Table I in the Data Supplement). To identify the target genes of these active DRE, we generated 63 4C-seq interaction data sets. We applied the following criteria for the identification of candidate genes: (1) the transcriptional start site colocalizes with a significant 4C-seq signal (P<1×0 -8 ) within 5 kb; (2) the susceptibility variant or any other variant in LD (r 2 ≥0.8) colocalizes with an active DRE signal in the cell type from which the 4C-seq signal was obtained; and (3) the gene is expressed (reads per kilobase of transcript per million reads sequenced > 0.5) in the studied cell type. With this approach, we identified 326 candidate genes (Table I in the Data Supplement), 77 in human male coronary endothelial cells, 84 in human male monocytes; and 165 in both cell types (Figure) . In total, we identified 294 candidate genes that were not previously reported by the CAD and LAS GWAS (Table I in the Data Supplement). We replicated 235/242 (97.1%) of the chromatin interactions with expressed genes that were identified in male coronary endothelial cells in female coronary endothelial cells (Table I in 
4C-Seq Identifies Candidate Genes in Novel Pathways
We performed cell type-specific pathway analysis of the candidate genes identified by 4C-seq combined with the candidate genes that were previously identified by the GWAS on CAD and LAS (Table II in the Data Supplement). Notably, these analyses revealed the hypoxia signaling in the cardiovascular system pathway in monocytes (P=0.01) and the nuclear factor (erythroid-derived 2)-like 2-mediated oxidative stress response pathway (P=4.68×10 -4 and P=0.026 in coronary endothelial cells and monocytes, respectively; Table II in the Data Supplement). These pathways are both involved in the cellular response to oxidative stress. Additionally, the 4C-seq approach revealed phosphatase and tensin analog (PTEN; a player in the hypoxia signaling in the cardiovascular system pathway) as a novel candidate gene (Table I in the Data Supplement). Although this gene was never reported via previous GWAS annotation, PTEN was found to be a likely candidate gene based on dose-dependently upregulation by statins through higher peroxisome proliferator-activated receptor-γ activity. 37 A mutation of PTEN led to inflammatory plaque characteristics in human atherosclerotic plaque, 38 and increased stability of PTEN was found to ameliorate atherosclerosis. 39 Furthermore, PTEN shares its upstream transcription regulator ZEB2 with CDKN2A and CDKN2B (enrichment P of overlap for ZEB2-regulated genes: 3.02×10 −3 in monocytes and 3.06×10 −3 in coronary endothelial cells). We reveal multiple novel pathways related to CVD, and we now show that PTEN physically interacts with a DRE at rs2246833 in monocytes (P interaction =2.36×10 −10 ).
Expression of Identified Genes Is Genotype Dependent
DREs exert their function through regulation of gene expression. We explored this mechanism by studying eQTL: the GWAS SNPs (or an SNP in LD; r 2 >0.8) that significantly affected the expression of the candidate genes identified by 4C-seq in the studied tissues (Table) . For the candidate genes identified by 4C-seq in coronary endothelial cells, we performed lookups within eQTL data of atherosclerotic artery wall and internal mammary artery in the STAGE cohort of patients undergoing cardiac bypass surgery. We identified 2 eQTL (FDR<0.1) in atherosclerotic artery wall (rs9818870: MRAS and rs2281727: SRR; Table IIIA in the Data Supplement). The SRR gene, that has not been reported previously, encodes for the serine racemase enzyme that is an endogenous ligand of the glycine site of N-methyl-D-aspartate receptors in the brain. Blockage of this site was found to prevent stroke damage. 40 Interestingly, a set of twice the Atherosclerosis Genes and Chromatin Organization number of genes from the same genetic locus that were not identified by 4C-seq as a target gene resulted in no significant eQTL in STAGE. Using the HaploReg tool, we additionally examined expression in aorta, coronary artery, and tibial artery tissue and identified another 7 eQTL for genes that we identified in coronary endothelial cells (Table IIIB in the Data Supplement), of which ARL3 and FAM117B were not reported before. Both genes are poorly studied in the context of CVD. Within the VAMP5-VAMP8-GGCX locus, we replicate rs1561198, that was previously reported to be an eQTL for GGCX in mammary artery by the CARDIoGRAMplusC4D investigators in the ASAP (Advanced Study of Aortic Pathology) study, 41 as an eQTL for GGCX in aorta and tibial artery.
For genes identified by 4C-seq in monocytes, we performed cis-eQTL analysis in monocytes from 370 patients undergoing coronary angiography for coronary artery atherosclerosis in the CTMM Circulating Cells cohort. 42 We identified 4 eQTL (FDR<0.1), of which the genes overlap with genes identified by 4C-seq in monocytes of these patients (rs12740374: PSRC1, rs1561198: VAMP8, rs2246833: LIPA, rs12413409: USMG5, Table IIIC in the Data Supplement). Previously, the CARDIoGRAMplusC4D investigators also identified rs1561198 as an eQTL for VAMP8 in lymphoblastoid cells and skin in the MuTHER (Multiple Tissue Human Expression Resource) study. 43 Inclusion of the previously published cardiovascular cohort of Zeller et al. 44 revealed 5 additional genes (Table IIID in the Data Supplement). The SNP that revealed the strongest association with gene expression of PSRC1 in monocytes of Center for Translational Molecular Medicine (rs7528419) is in perfect LD (1) with rs12740374 in the SORT1 region. Interestingly, although the minor allele of the latter SNP is known to increase SORT1 expression in liver, we found no such association between rs7528419 and SORT1 expression in monocytes (nominal P=0.87). In addition, we found an association between higher PSRC1 expression in monocytes with a more severe atherosclerotic phenotype identified by a higher atherosclerotic burden, quantified using the SYNTAX score (P=0.003). This association with high atherosclerosis burden could not solely be explained by low-density lipoprotein levels, the putative mechanism through which SORT1 expression affects CVD phenotypes (P when corrected for circulating low-density lipoprotein levels =0.01). Expression of PSRC1 in whole blood has previously been associated with CVD in an Asian population. 45 Largely because of the functional significance of the minor allele of rs12740374 as a transcription factor-binding site that increases SORT1 expression directly, no further attention has been given to alternative candidate genes in the SORT1 region. With our 4C-seq approach in monocytes, we here show first evidence that the expression of PSRC1, a candidate gene in the SORT1 locus, is genotype dependent, expressed in monocytes and related to the severity of atherosclerosis. This example further supports the implication of our additionally identified candidate genes in CVD.
Additional Genetic Annotation
We further explored current genetic knowledge for the candidate genes identified through 4C-seq (Table; Table IV -VII in the Data Supplement). First, if the candidate genes are effector genes of the DREs within CVD susceptibility loci, one would expect the genes to be enriched for (common) variants associated with CVD. Using the VEGAS algorithm, we concatenated GWAS P values of all SNPs in or within 50 kb of a gene into a P value for that particular gene. This way, we studied the genes identified by 4C-seq in published and unpublished GWAS data studying a total of 22 traits, either surrogate markers of atherosclerosis or known risk factors for CVD (Table IV in the Data Supplement). Of all 326 candidate genes, 33 showed a significant association (P<0.05/(22×326)=6.97×10 −6 ) with CAD in the CARDIoGRAMplusC4D GWAS and 149 were nominally associated with CAD in the CARDIoGRAMplusC4D GWAS (significant enrichment, 149/326: binomial P=2.9×10 -102 ). Additionally, we found 7 genes that were significantly associated with body mass index in Genetic Investigation of ANthropometric Traits and 29 genes that were significantly associated with at least 1 lipid trait in Global Lipids Genetics Consortium.
Second, we annotated the prioritized interacting genes from our 4C-seq experiment with phenotypic information of mouse models within the Mouse Genome Informatics database (www.informatics.jax.org). We found murine phenotypic information on 144 mouse homologues (Table V in the Data Supplement). Knockout of 67 of them resulted in a phenotype related to CVD (significant enrichment, 67/144: binomial P=1.36×10 −47 ), such as abnormal blood vessel morphology (Col4a1, Cxcl12, Epor, Shc1, Tcf7l1), altered circulating fatty acid levels (Csf2, Kdm3a, Ldlr, Lipa, Pten), and impaired vascular contractility (Acta2). Human variants in ACTA2 are associated with early onset stroke and myocardial infarction. 46 Knockout of 2 candidate gene murine homologs affected development of atherosclerotic lesions, namely Ldlr (accelerated development of atherosclerosis) and Shc1 (resistance to diet-induced atherosclerosis). The p66 isoform of human SHC1 is implicated in reactive oxygen species generation, and its knockdown in endothelial cells of obese mice attenuated production of these radicals and of fatty acids oxidation. 47 Third, we investigated the biological effect of human knockout variation of the candidate genes to study druggability. We queried 2 data sets of available information on SNPs and insertion/deletion variants that cause human functional knockouts. 29, 30 We found human knockouts, caused by nonsense, splice, or frameshift variants, for 89 candidate genes (Table VI in the Data  Supplement) .
Fourth, using a custom-built drug discovery pipeline, we found available compounds to target 50 of the candidate genes (Table VIIA in the Data Supplement). These drugs showed a relative overrepresentation for usage as immunomodulating agents (P=0.012 in coronary endothelial cells and P<0.001 in monocytes; Table VIIB in the Data Supplement) .
Together, these findings provide further evidence that by using the 4C-seq method, we identified additional candidate target genes for human atherosclerotic disease.
Discussion
Based on 3D chromatin-chromatin interactions with DREs that colocalize with previously identified susceptibility loci, Atherosclerosis Genes and Chromatin Organization we present 294 additional candidate genes for CAD and LAS that are of potential interest in the pathophysiology of human atherosclerotic disease. This study is the first to systematically study the human chromatin interactions of the CARDIoGRAMplusC4D and METASTROKE loci. Many of the additional genes have not been implicated in atherosclerosis before. Our approach, from a DNA regulatory point of view, complements conventional methods for candidate gene identification of GWAS susceptibility, can help further unravel diseases with a complex genetic background, and pave the way for cell type-specific drug development.
We have highlighted the 4C candidate genes that we could annotate via additional analyses and that, therefore, have known or foreseeable effects on CVD. Based on tissue-specific pathway analyses, we highlighted PTEN that is known to be upregulated by statins and to possess effects on atherosclerosis. [37] [38] [39] Furthermore, based on eQTL studies, we identified SRR, the effect of which was previously implicated in stroke, 40 and USMG5, that was previously associated with white matter hyperintensities in the brain. 48 Of special interest is the finding of an alternative mechanism by which the susceptibility locus that contains rs7528419 (SORT1 region) may exert its effect. Using 4C-seq, we identified a physical interaction between an active regulatory element that overlaps rs7528419 and PSRC1 in monocytes. Moreover, we found an association between rs7528419 and the expression of PSRC1 in monocytes and an association between PSRC1 expression and atherosclerosis severity. This association was independent of low-density lipoprotein levels, which is the putative mechanism of rs12740374, an SNP in perfect LD (1.0) with rs7528419 that was previously found to increase SORT1 expression in liver.
Mapping the SNPs that identify susceptibility loci in GWAS to genes that affect a complex disease, such as CVD, is a challenging task. By annotating the locus with the linearly closest gene, the 3D conformation of chromatin is inadvertently not taken into account. Many of the additional candidate genes we report are located outside the GWAS susceptibility loci. Using 5C (chromosome conformation capture carbon copy), the importance of studying 3D interactions has been highlighted previously; in a sample of 628 transcriptional start site from the ENCODE project, only 7% of the over 1000 long-range looping interactions were with the nearest gene. 10 In a previous effort to identify candidate genes based on DNA regulatory mechanisms, 33 enhancers in the 9p21 locus were scrutinized. 49 Interestingly, the chromatin interaction between the enhancers identified by 3C (chromatin conformation capture) was found to be remodeled on treatment with interferon-γ in human umbilical vein endothelial cells. In our 4C-seq experiment, we confirmed the physical chromatin-chromatin interaction between the 9p21 susceptibility locus and several candidate genes, among which are interferons, in human coronary endothelial cells and monocytes. However, we found that these genes were not actively expressed in these cell types and, therefore, did not consider them any further.
There are some limitations to this study. First, there is no consensus about the gold standard approach to analysis of 4C-seq data. For example, we used a conservative cutoff for calling a chromatin-chromatin interaction (P<10-8). Altering this cutoff may result in more candidate genes. However, this likely leads to more false-positive results. We, therefore, report a quantitative measure for the P value of the interaction of the DRE with the proposed candidate gene to enable the reader to take these considerations into account when interpreting the data. Second, while 4C-sequencing enables us to look at physical interactions, these interactions do not necessarily mean that the expression in the studied tissue is in fact regulated by the association locus or even expressed. We, therefore, decided to only report genes that are actively expressed in the studied tissues. Furthermore, we found no eQTL association between the SNP of interest and any of the genes in the vicinity of the genes that were identified by 4C-sequencing, indicating that the resolution of the technique is sufficient to distinguish between candidate genes and less relevant genes within a genomic region. A more accurate cell type-specific mapping of susceptibility loci to candidate genes in humans is of paramount importance for the development of specific compounds in the pharmaceutical industry. The genes we identified display only partial overlap between coronary endothelial cells and monocytes. This finding stresses the importance of cell-specific approaches to grasp the complex biology of atherosclerotic disease. It also highlights the possibility to develop cell-specific compounds to target atherosclerotic disease. Our results, therefore, underline the need to investigate cell type-specific 3D chromatin conformation in future functional follow-up of GWAS data.
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